Live Analyst Rating Changes 1526 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Matthew Taylor
JEF
Matthew Taylor
Wall Street Analyst
★★☆☆☆
#2184
on 13Foresight · ranked by our own returns
47%
Success Rate
+1.8%
Average Return
16 of 34 calls profitable · -2154.6% vs benchmark
📈 Across the calls we could measure, roughly 47% of Matthew Taylor's ratings turned a profit when each position was held for 1 year — averaging +1.8% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

50 Buy 6 Hold 0 Sell
Matthew's Stock Coverage 39 ratings · 2026-06-21
Company Date Position Consensus Price Target 1-Yr Return
SYK
Stryker
Jun 18, 2026 BUY Strong Buy
+24.0% avg upside
36 analysts
$455.00
47.74% Upside
·
EW
Edwards Lifesciences
May 27, 2026 BUY Strong Buy
+11.7% avg upside
34 analysts
$102.00
16.76% Upside
+0.2%
BSX
Boston Scientific
May 19, 2026 BUY Strong Buy
+72.9% avg upside
38 analysts
$100.00
120.74% Upside
-20.3%
MDT
Medtronic
Apr 24, 2026 HOLD Buy
+23.5% avg upside
38 analysts
$95.00
19.67% Upside
-4.8%
ABT
Abbott Laboratories
Apr 17, 2026 BUY Strong Buy
+31.2% avg upside
35 analysts
$135.00
52.63% Upside
-8.7%
LNTH
Lantheus
Mar 18, 2026 BUY Strong Buy
-27.9% avg upside
20 analysts
$110.00
5.91% Upside
+30.4%
PODD
Insulet
Feb 19, 2026 BUY Strong Buy
+79.0% avg upside
32 analysts
$400.00
174.45% Upside
-41.5%
GEHC
GE Healthcare Technologies Inc
Feb 18, 2026 BUY Strong Buy
+36.0% avg upside
20 analysts
$105.00
70.50% Upside
-25.7%
DXCM
Dexcom
Feb 13, 2026 BUY Strong Buy
+38.6% avg upside
32 analysts
$112.00
54.50% Upside
+4.5%
BAX
Baxter International
Feb 12, 2026 HOLD Hold
+49.6% avg upside
23 analysts
$19.00
4.48% Downside
+11.3%
GMED
Globus Medical
Jan 08, 2026 BUY Strong Buy
+21.0% avg upside
24 analysts
$115.00
45.15% Upside
-15.0%
TNDM
Tandem Diabetes Care
Nov 07, 2025 BUY Strong Buy
+116.0% avg upside
29 analysts
$48.00
213.81% Upside
+4.0%
VREX
Varex Imaging
Oct 03, 2025 HOLD Strong Buy
+92.1% avg upside
9 analysts
$12.00
14.05% Upside
-18.8%
SI
Shoulder Innovations, Inc.
Aug 25, 2025 BUY Strong Buy
+13.2% avg upside
5 analysts
$19.00
2.45% Upside
+49.8%
LIVN
LivaNova
Aug 07, 2025 BUY Strong Buy
+0.2% avg upside
14 analysts
$80.00
1.82% Upside
+44.3%
ESTA
Establishment Labs Holdings
Aug 07, 2025 BUY Strong Buy
-1.6% avg upside
12 analysts
$63.00
25.67% Downside
+135.8%
ZBH
Zimmer Biomet Holdings
Aug 07, 2025 HOLD Buy
+27.6% avg upside
37 analysts
$110.00
25.14% Upside
-9.1%
SIBN
SI-Bone
Aug 05, 2025 BUY Strong Buy
+60.4% avg upside
18 analysts
$28.00
76.68% Upside
-11.5%
ALUR
Allurion Technologies
Jun 04, 2025 BUY Strong Buy
+1753.4% avg upside
4 analysts
$18.00
3003.41% Upside
-71.0%
ISRG
Intuitive Surgical
May 02, 2025 HOLD Strong Buy
+29.4% avg upside
36 analysts
-13.5%
BDX
Becton Dickinson
May 01, 2025 BUY Buy
+35.5% avg upside
25 analysts
$255.00
77.12% Upside
+14.6%
TFX
Teleflex
May 01, 2025 HOLD Buy
+42.1% avg upside
19 analysts
$145.00
14.21% Upside
-2.4%
AU:TLX
Telix Pharmaceuticals
Apr 28, 2025 BUY Strong Buy
+75.0% avg upside
13 analysts
$34.50
138.02% Upside
·
INMD
InMode
Apr 14, 2025 BUY Buy
+41.7% avg upside
9 analysts
$15.00
11.85% Upside
-6.2%
SENS
Senseonics Holdings
Mar 04, 2025 SELL Strong Buy
+124.8% avg upside
13 analysts
$6.00
11.07% Downside
+51.1%
RMD
Resmed
Oct 25, 2024 HOLD Buy
+25.4% avg upside
27 analysts
$245.00
29.84% Upside
+2.2%
IART
Integra Lifesciences
Jul 16, 2024 BUY Buy
+136.2% avg upside
21 analysts
$48.00
173.11% Upside
-61.9%
CNMD
Conmed
Feb 01, 2024 HOLD Hold
+81.2% avg upside
12 analysts
$105.00
222.32% Upside
-13.4%
OBIO
Orchestra BioMed Holdings
Jan 19, 2024 BUY Strong Buy
+232.1% avg upside
9 analysts
$14.00
250.95% Upside
-39.5%
CH:SOON
Sonova Holding AG
Oct 28, 2022 HOLD Sell
+14.3% avg upside
17 analysts
$255.00
32.07% Upside
·
PEN
Penumbra
Oct 12, 2022 BUY Buy
+4.4% avg upside
23 analysts
$230.00
27.59% Downside
+7.1%
UTRS
Minerva Surgical
Mar 09, 2022 BUY Buy
+799999900.0% avg upside
4 analysts
$14.00
1399999900.04% Upside
·
BFLY
Butterfly Network
Mar 01, 2022 HOLD Strong Buy
-48.9% avg upside
7 analysts
$5.50
38.17% Downside
-54.2%
BKNG
Booking Holdings
Feb 07, 2022 BUY Strong Buy
+530.4% avg upside
54 analysts
+0.2%
NL:PHIA
Koninklijke Philips N.V.
Jan 25, 2022 BUY Buy
+31.3% avg upside
20 analysts
$49.00
108.43% Upside
·
DE:SHL
Siemens Healthineers AG
Dec 06, 2019 HOLD Strong Buy
+51.7% avg upside
22 analysts
·
LFWD
Lifeward
Mar 08, 2018 SELL Strong Buy
+5.4% avg upside
8 analysts
$1.00
85.59% Downside
+80.4%
ANGO
AngioDynamics
Jul 19, 2017 HOLD Strong Buy
+39.9% avg upside
9 analysts
$16.00
31.69% Upside
+41.2%
EVARF
Lombard Medical
May 12, 2016 HOLD Hold
+249999900.0% avg upside
1 analyst
$2.50
249999900.01% Upside
·
🔒 34 more ratings — with price targets, crowd consensus and our measured returns.
Free account unlocks every analyst's full coverage table.
Matthew Taylor — Frequently Asked Questions
How accurate are Matthew Taylor's stock ratings?
Based on the calls 13Foresight could measure, about 47% of Matthew's ratings were profitable over a one-year hold, with an average return of +1.8% per rating, or -2154.6% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Matthew ranked on 13Foresight?
Matthew Taylor is currently ranked #2184 with a 2-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Matthew cover?
Matthew most recently has ratings on SYK, EW, BSX, MDT, ABT, LNTH, PODD, GEHC, DXCM, BAX, GMED, TNDM and 27 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.